 Shares of Acorda Therapeutics NASDAQ:ACOR moved higher by 20 after the company reported Q2 results.Quarterly Results Earnings per share rose 36.36 year over year to 0.35, which beat the estimate of 0.48.Revenue of 33,617,000 decreased by 32.84 from the same period last year, which beat the estimate of 27,500,000.Outlook Earnings guidance hasnt been issued by the company for now.Acorda Therapeutics hasnt issued any revenue guidance for the time being.Conference Call Details Date: Aug 04, 2020View more earnings on ACORTime: 04:30 PMET Webcast URL: Action 52-week high: 5.5652-week low: 0.60Price action over last quarter: down 24.40Company Profile Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinsons disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.See more from Benzinga Stocks That Hit 52-Week Lows On Thursday 20 Healthcare Stocks Moving In Wednesdays Pre-Market Session Stocks That Hit 52-Week Lows On TuesdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 